This is the first Bayesian NMA to show promising, significant efficacy and safety for Erlo+Bev, Erlo+Bev+Plat and Osi over other available treatments for advanced EGFR-mutant NSCLC, considering the balance between PFS and OS. This evidence concerns the gene EGFR and non-small cell lung carcinoma.